Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Kyle Rose joins Sam Chang in discussing his team’s findings regarding the impact of cell-free urinary DNA on non-muscle invasive bladder cancer patients. This...

In this exclusive VJSession, join GU cancer experts Sophia Kamran (Massachusetts General Hospital and Harvard Medical School, Boston, MA), Himanshu Nagar (Weill Cornell Medicine...

...

The safety and efficacy of the immune checkpoint inhibitor atezolizumab plus the VEGF TKI tivozanib is being investigated in patients with unresectable or metastatic...

Treatment with the antibody-drug conjugate sacituzumab govitecan-hziy achieved an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer who experienced disease...

The addition of the poly (ADP ribose) polymerase (PARP) inhibitor talazoparib to the androgen receptor signaling inhibitor enzalutamide achieved a statistically significant and clinically...

Michael S. Leapman, MD, MHS, highlights the need for clearer information regarding genomic testing for patients with prostate...

Michael S. Leapman, MD, MHS, highlights the need for clearer information regarding genomic testing for patients with prostate...

By Alice Goodman Posted: 3/23/2023 11:07:00 AM Last Updated: 3/23/2023 11:22:11 AM The addition of the androgen receptor inhibitor darolutamide to androgen-deprivation therapy and...

This phase III trial, however, did not meet statistical significance for its primary endpoint in the overall study population. The addition of abiraterone acetate...